[Crypotanshione reduces the expression of metadherin in DU145 prostate cancer cells]
Objective:
To investigate the effects of crypotanshinone (CPT) on the proliferation and apoptosis of DU145 prostate cancer cells as well as on the metadherin expression and the downstream PI3K/AKT signaling pathway in the DU145 cells.
Methods:
We treated DU145 prostate cancer cells with different concentrations of CPT for 24, 48, and 72 hours followed by evaluation of the proliferation and apoptosis of the cells by MTT assay and TUNEL, respectively. We determined the expressions of metadherin protein and mRNA in the DU145 cells by Western blot and RT-PCR respectively at different time points after CPT treatment. We also detected the expressions of the proteins metadherin, AKT, p-AKT, and Bcl-2 in the CPT-treated DU145 cells at 48 hours.
Results:
CPT significantly inhibited the proliferation of the DU145 cells in a dose- and time-dependent manner (P < 0.05). After treatment with 10 µmol/L CPT for 24, 48, and 72 hours, the apoptosis rates of the DU145 cells were (29.42 ± 4.51), (55.07 ± 5.67) and (70.84 ± 4.66)%, respectively, significantly higher than (3.1 ± 2.48)% in the control group (P < 0.05). The expression of metadherin was remarkably downregulated at the transcription and translation levels (P < 0.05) and the expressions of the AKT signaling pathway and the Bcl-2 protein were markedly inhibited in the DU145 cells after treated with 10 µmol/L CPT for 48 hours (P < 0.05).
Conclusion:
CPT can inhibit the proliferation and induce the apoptosis of DU145 prostate cancer cells, which may be associated with its suppression of the downstream PI3K/AKT signaling pathway by reducing the expression of metadherin in the DU145 cells.
Insights
Cryptotanshinone (CPT) effectively inhibits prostate cancer cell growth and promotes apoptosis. This action is linked to CPT
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
- Metadherin (MTDH) is implicated in cancer progression and signaling pathways.
- The PI3K/AKT pathway is crucial in cell survival and proliferation.
Purpose of the Study:
- To evaluate the anti-cancer effects of cryptotanshinone (CPT) on DU145 prostate cancer cells.
- To investigate CPT's impact on metadherin expression and the PI3K/AKT pathway.
Main Methods:
- DU145 cells were treated with varying CPT concentrations and durations.
- Cell proliferation and apoptosis were assessed using MTT assays and TUNEL staining.
- Metadherin, AKT, and Bcl-2 expression levels were analyzed via Western blot and RT-PCR.
Main Results:
- CPT significantly inhibited DU145 cell proliferation in a dose- and time-dependent manner.
- CPT treatment markedly increased apoptosis rates in DU145 cells.
- CPT downregulated metadherin expression and inhibited the PI3K/AKT pathway and Bcl-2 protein.
Conclusions:
- CPT exhibits potent anti-prostate cancer activity by inhibiting proliferation and inducing apoptosis.
- CPT's mechanism involves the downregulation of metadherin and subsequent suppression of the PI3K/AKT signaling pathway.
